Akebia Therapeutics
Akebia Therapeutics is a fully integrated biopharmaceutical company dedicated to addressing complications of kidney disease. Since its founding in 2007, it has developed unique therapeutics with a focus on kidney health, with two FDA-approved products. The company emphasizes innovation, collaboration, and tenacity to improve lives impacted by kidney disease, working closely with healthcare providers, advocacy organizations, and partners globally.
Industries
Nr. of Employees
medium (51-250)
Akebia Therapeutics
245 First Street, Suite 1400, Cambridge, MA 02142
Patents
Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid
US-12269802-B2
View DetailsProcess for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US-11713298-B2
View DetailsSolid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US-11690836-B2
View Details
Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid
US-12269802-B2
View DetailsProcess for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US-11713298-B2
View DetailsSolid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US-11690836-B2
View DetailsProducts
Oral HIF-PHI tablet for anemia in chronic kidney disease
An oral small-molecule HIF prolyl hydroxylase inhibitor developed and approved for treatment of anemia associated with chronic kidney disease; intended to increase erythropoiesis via HIF pathway modulation.
Oral ferric citrate formulation for hyperphosphatemia and iron replacement
An oral ferric citrate formulation developed and marketed for control of serum phosphorus in patients with chronic kidney disease and for treatment of iron deficiency in certain renal populations.
Oral HIF-PHI tablet for anemia in chronic kidney disease
An oral small-molecule HIF prolyl hydroxylase inhibitor developed and approved for treatment of anemia associated with chronic kidney disease; intended to increase erythropoiesis via HIF pathway modulation.
Oral ferric citrate formulation for hyperphosphatemia and iron replacement
An oral ferric citrate formulation developed and marketed for control of serum phosphorus in patients with chronic kidney disease and for treatment of iron deficiency in certain renal populations.
Services
Evaluation and execution of license agreements, co-development collaborations, and regional commercialization partnerships for renal and related therapeutics.
Support for clinical investigators, site participation and enrollment in ongoing clinical programs, including coordination of remote monitoring where appropriate.
Programs to support patients with medication reimbursement and access to prescribed therapies.
Evaluation and execution of license agreements, co-development collaborations, and regional commercialization partnerships for renal and related therapeutics.
Support for clinical investigators, site participation and enrollment in ongoing clinical programs, including coordination of remote monitoring where appropriate.
Programs to support patients with medication reimbursement and access to prescribed therapies.
Expertise Areas
- Clinical trial management for renal indications
- Hypoxia-inducible factor pathway drug development
- Anemia and mineral metabolism in chronic kidney disease
- Oral small-molecule formulation development
Key Technologies
- HIF prolyl hydroxylase inhibition (HIF-PHI) platform
- Oral small-molecule formulation
- Oral iron-based therapeutic formulation
- Clinical trial conduct and remote monitoring